Serizawa Toru, Higuchi Yoshinori, Ono Junichi, Matsuda Shinji, Nagano Osamu, Iwadate Yasuo, Saeki Naokatsu
Gamma Knife House, Department of Neurosurgery, Chiba Cardiovascular Center, Ichihara, Chiba, Japan.
J Neurosurg. 2006 Dec;105 Suppl:86-90. doi: 10.3171/sup.2006.105.7.86.
The authors analyzed the effectiveness of Gamma Knife surgery (GKS) for metastatic brain tumors without adjuvant prophylactic whole-brain radiotherapy (WBRT). Salvage GKS was performed as the sole treatment for new distant lesions.
Among 1127 patients in whom new brain metastases had been diagnosed, 97 who met one or more of the following three criteria were excluded from the study: any surgically inaccessible huge (>/= 35 mm) lesion; tumor number and size requiring an internal skull dose exceeding 10 J; or symptomatic carcinomatous meningitis. Thus, 1030 consecutive patients formed the basis for this study. Huge tumors were totally removed, whereas smaller lesions were treated with GKS. No adjuvant WBRT was given prior to GKS, and new distant lesions were appropriately retreated with GKS. Overall, neurological and new lesion-free survival curves were calculated and the prognostic values of covariates were obtained. In total, 1853 separate GKS sessions were required to treat 10,163 lesions.The patients' median overall survival period was 8.6 months. Neurological survival and new lesion-free rates at 1 year were 89.1 and 49.3%, respectively. In a multivariate analysis, the significant factors for poor prognosis were the development of more than four new brain metastases and active extracranial disease.
In meeting the goal of preventing neurological death and maintaining activities of daily living for patients with brain metastases, GKS alone provides excellent palliation without prophylactic WBRT. New distant lesions were quite well controlled with GKS salvage treatment alone.
作者分析了伽玛刀手术(GKS)治疗无辅助预防性全脑放疗(WBRT)的脑转移瘤的有效性。挽救性GKS作为新的远处病变的唯一治疗方法。
在1127例诊断为新发脑转移瘤的患者中,97例符合以下三项标准中的一项或多项,被排除在研究之外:任何手术无法触及的巨大(≥35mm)病变;肿瘤数量和大小需要颅内剂量超过10J;或症状性癌性脑膜炎。因此,1030例连续患者构成了本研究的基础。巨大肿瘤被完全切除,较小的病变则采用GKS治疗。在GKS之前未给予辅助WBRT,新的远处病变则适当采用GKS再次治疗。总体而言,计算了神经功能和无新病变生存曲线,并获得了协变量的预后价值。总共需要1853次单独的GKS治疗10163个病变。患者的中位总生存期为8.6个月。1年时的神经功能生存率和无新病变率分别为89.1%和49.3%。在多变量分析中,预后不良的显著因素是出现超过四个新的脑转移瘤和活跃的颅外疾病。
为实现预防脑转移瘤患者神经功能死亡和维持日常生活活动的目标,单独使用GKS无需预防性WBRT即可提供出色的姑息治疗。单独使用GKS挽救性治疗对新的远处病变控制良好。